Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 1164-1173 | ISSN:2251-6727

Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE): A Comprehensive Review of Pathophysiology, Diagnosis, and Therapeutic Advances

Parameshwar S.M[1], Jothish Ram M[1], Annalakshmi S[1], John Peter S[1], Dr. Dheenadhayalan M*[2], Dr. K. Karthickeyan[3],

[1]PharmD, Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai, Tamil Nadu, India

[2]Assistant Professor, Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai, Tamil Nadu, India

[3]Professor and Head, Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai, Tamil Nadu, India

***Corresponding author**

Dr. Dheenadhayalan M, Mail ID: drdheenadhayalanmap@gmail.com, ORCID ID - 0009-0002-0225-7806

Assistant Professor, Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology & Advanced Studies, Chennai, Tamil Nadu, India

(Received: 27 September 2025 Revised: 05 October 2025 Accepted: 18 November 2025)

KEYWORDS
Mitochondrial Neurogastrointestinal Encephalopathy, Thymidine phosphorylase deficiency, Mitochondrial DNA depletion, Gastrointestinal dysmotility, Hematopoietic stem cell transplantation.

ABSTRACT:
Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE) is a rare autosomal recessive multisystem disorder caused by mutations in the TYMP gene, leading to thymidine phosphorylase deficiency and subsequent mitochondrial DNA instability. This results in profound mitochondrial dysfunction primarily affecting the gastrointestinal and nervous systems. Clinically, MNGIE manifests as progressive gastrointestinal dysmotility, including chronic intestinal pseudo-obstruction, nausea, vomiting, diarrhea, and severe cachexia. Neurological features such as peripheral neuropathy, ophthalmoplegia, ptosis, and diffuse leukoencephalopathy further complicate the clinical picture. The disease typically presents in early adulthood but can manifest at any age, with significant variability in severity and progression. Diagnosis involves clinical evaluation, detection of elevated plasma thymidine and deoxyuridine, reduced thymidine phosphorylase activity, characteristic MRI findings, nerve conduction studies, and genetic testing for TYMP mutations. Therapeutic options remain limited but include allogeneic hematopoietic stem cell transplantation to restore enzymatic activity, experimental enzyme replacement therapies, gene therapy, and supportive care for symptom management. Early diagnosis and emerging molecular therapies offer hope for improved outcomes, although the prognosis remains poor due to the progressive and multisystem nature of the disease. This comprehensive review synthesizes current understanding of MNGIE's pathophysiological mechanisms, diagnostic criteria, and recent advances in treatment strategies, highlighting challenges and future directions in managing this devastating disorder.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 1164-1173 | ISSN:2251-6727

1. Introduction

Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE) is a rare autosomal recessive disorder caused primarily by mutations in the TYMP gene, which encodes the enzyme thymidine phosphorylase (TP).[1] TP deficiency leads to systemic accumulation of the nucleosides thymidine (dThd) and deoxyuridine (dUrd), disrupting the delicate balance of mitochondrial deoxynucleotide triphosphate (dNTP) pools essential for mitochondrial DNA (mtDNA) replication and repair. This imbalance particularly causes an excessive concentration of dTTP and a secondary depletion of dCTP within mitochondria, which impairs mtDNA replication fidelity and stability.[1] These biochemical abnormalities induce mtDNA depletion, multiple deletions, and point mutations, culminating in mitochondrial dysfunction characterized by defective oxidative phosphorylation and energy production. This mitochondrial failure predominantly affects tissues with high energy demands, notably the gastrointestinal tract and nervous system, explaining the multisystem manifestations of MNGIE.[1,2]

Clinical onset varies widely, from infancy to adulthood, with symptoms progressing gradually. The hallmark features include severe gastrointestinal dysmotility causing chronic intestinal pseudo-obstruction and malnutrition, peripheral neuropathy, ophthalmoplegia, and leukoencephalopathy.[2] The progressive nature of mitochondrial DNA damage accounts for the severe morbidity and early mortality seen in affected individuals. Experimental evidence from cell culture and animal models underscores that the pathogenic mechanism is primarily driven by nucleotide pool imbalances—especially dCTP depletion—not merely the absence of enzyme activity. This has therapeutic implications, guiding strategies to restore nucleotide balance alongside enzyme replacement.[3] MNGIE arises from TP deficiency causing toxic nucleoside accumulation, mitochondrial dNTP imbalance, mtDNA instability, and multisystem dysfunction with progressive clinical decline and high mortality risk. Early recognition and targeted therapies are critical to improving outcomes in this devastating genetic disorder.

2. Pathophysiology

MNGIE pathophysiology results from mutations in the nuclear TYMP gene that encodes thymidine phosphorylase (TP), an enzyme critical for the catabolism of thymidine (dThd) and deoxyuridine (dUrd) into their respective bases thymine and uracil.[2] Loss-of-function mutations, which can be homozygous or compound heterozygous, profoundly reduce or abolish TP enzyme activity, leading to systemic accumulation of dThd and dUrd. The resultant excess nucleosides cause a pronounced imbalance in mitochondrial deoxynucleotide triphosphate (dNTP) pools, characterized by increased dTTP and decreased dCTP availability.[3] This disturbed nucleotide homeostasis undermines mitochondrial DNA (mtDNA) polymerase function, impairing faithful replication and repair of mtDNA within mitochondria.

As a consequence, mtDNA undergoes multiple abnormalities including depletion, point mutations, and large-scale deletions. Since mtDNA encodes essential components of the oxidative phosphorylation (OXPHOS) system, these defects culminate in mitochondrial respiratory chain dysfunction and diminished cellular energy production.[4] High-energy demanding tissues such as gastrointestinal smooth muscle and nervous tissue are particularly vulnerable to this energy deficit.

Histopathologically, this mitochondrial dysfunction manifests as smooth muscle fiber atrophy and mitochondrial proliferation ("megamitochondria") within GI tissues, leading to profound gastrointestinal dysmotility.[5] Peripheral neuropathy and diffuse leukoencephalopathy on MRI are characteristic neurological features caused by the mitochondrial energy failure and subsequent neuronal degeneration. The combination of GI and neurological manifestations reflects the multisystem impact of mitochondrial failure secondary to TYMP mutations.

Genotype-phenotype correlations show that patients with complete loss of TP activity (homozygous mutations) have earlier disease onset and more severe phenotypes, whereas compound heterozygous mutations often result in partial enzyme activity and milder, later-onset presentations.[6] This variability is likely related to the degree of nucleotide pool imbalance and consequent mtDNA damage.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(6), 1164-1173 | ISSN:2251-6727



Figure 1. Molecular defect in MNGIE. Mutations in the TYMP gene cause thymidine phosphorylase (TP) deficiency, leading to accumulation of thymidine and deoxyuridine. This disrupts mitochondrial deoxynucleotide balance, impairing mtDNA repair and function. TP: thymidine phosphorylase; MNGIE: mitochondrial neurogastrointestinal encephalomyopathy; mtDNA: mitochondrial DNA.

3. Clinical Manifestations

Patients with Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE) typically present with a triad of progressive gastrointestinal dysmotility, neurological deficits, and severe cachexia, reflecting the multisystem impact of mitochondrial dysfunction.[1,4] Gastrointestinal symptoms dominate the clinical picture, with nearly all patients experiencing chronic intestinal pseudo-obstruction (CIPO), which manifests as impaired propulsion of food through the digestive tract due to smooth muscle and enteric nervous system dysfunction. This leads to early satiety, nausea, vomiting, diarrhea, abdominal pain, bloating, and frequent episodes of intestinal distension.[7] The resulting malabsorption and bacterial overgrowth contribute significantly to progressive weight loss and cachexia, often leaving patients extremely thin and nutritionally compromised.

Neurological symptoms include peripheral neuropathy characterized by tingling, numbness, and weakness predominantly in the distal limbs. Patients also develop ocular muscle involvement, presenting as ptosis (drooping eyelids) and progressive external ophthalmoplegia, which restricts eye movements.[1-5] Hearing loss is common, related to mitochondrial dysfunction affecting auditory pathways. Brain MRI typically reveals diffuse, symmetrical leukoencephalopathy—white matter abnormalities that are often asymptomatic but diagnostic when present.

Muscular and systemic manifestations include severe muscle wasting and weakness that compound the nutritional deficits, as well as early-onset diverticulosis or diverticulitis stemming from structural intestinal abnormalities.[8,9] Other less common features may include short stature and hormonal imbalances.

Together, these symptoms reflect the mitochondrial energy deficit in tissues with high metabolic demands, especially gastrointestinal smooth muscle and peripheral nerves, driving the progressive morbidity and early mortality associated with MNGIE. Effective clinical management requires multidisciplinary care addressing gastrointestinal motility, nutritional support, neurological symptoms, and vigilant monitoring for complications.

Table 1. Major Clinical Manifestations of Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE)

System	Clinical Features
Gastrointestinal	Chronic intestinal pseudo-obstruction, nausea, vomiting, diarrhea, abdominal pain, malabsorption, cachexia

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(6), 1164-1173 | ISSN:2251-6727

Neurological	Peripheral neuropathy (sensory/motor), ophthalmoplegia, ptosis, leukoencephalopathy on MRI, hearing loss
Muscular/Systemic	Muscle wasting, early-onset diverticulosis/diverticulitis, weight loss, fatigue
Others	Endocrine abnormalities, cardiac arrhythmias, psychiatric symptoms

4. Diagnosis

Diagnosing Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE) involves a multidisciplinary approach combining clinical, biochemical, imaging, and genetic assessments.[2] Clinically, a physician first evaluates hallmark symptoms such as severe gastrointestinal dysmotility (including chronic intestinal pseudo-obstruction, nausea, vomiting, diarrhea), cachexia from malnutrition, peripheral neuropathy, extraocular muscle weakness (ptosis and ophthalmoplegia), and neurological deficits.[10] These symptoms lead to suspicion of a mitochondrial disorder with multisystem involvement.

4.1 Clinical and Laboratory Evaluation

Clinical and laboratory evaluation for MNGIE begins with a detailed patient history and physical examination focusing on both gastrointestinal and neurological signs. Gastrointestinal symptoms commonly include early satiety, nausea, vomiting, abdominal pain, diarrhea, difficulty swallowing (dysphagia), and features of chronic intestinal pseudo-obstruction due to impaired muscle and nerve function in the GI tract.[11-14] Neurologically, patients often present with peripheral neuropathy characterized by numbness, tingling, and weakness predominantly in the distal limbs, as well as extraocular muscle weakness causing ptosis and ophthalmoplegia, and sometimes hearing loss.[6] These clinical features guide suspicion toward a mitochondrial disorder involving multisystem dysfunction.

Laboratory tests provide critical diagnostic clues. Measurement of plasma thymidine and deoxyuridine levels shows significant elevation, often five to ten times above normal, owing to deficient thymidine phosphorylase (TP) activity leading to toxic nucleoside accumulation.[13] Elevated lactic acid levels may also be seen, reflecting mitochondrial respiratory chain dysfunction. Electrolyte disturbances can occur secondary to gastrointestinal malabsorption and chronic diarrhea. Definitive biochemical confirmation involves quantitative assays of TP enzyme activity in leukocytes or platelets, which are markedly reduced (usually less than 8% of normal activity).[4] These biochemical abnormalities are pathognomonic for MNGIE.

Together, the clinical presentation of progressive gastrointestinal dysmotility and peripheral neuropathy combined with biochemical evidence of nucleoside accumulation and TP deficiency support the diagnosis of MNGIE.[15] Early recognition through this thorough clinical and laboratory evaluation is vital to prompt genetic confirmation and consideration of emerging treatment options.

4.2 Imaging and Functional Studies

Imaging and functional studies are crucial for diagnosing and characterizing MNGIE. Brain MRI typically reveals diffuse, symmetrical leukoencephalopathy characterized by signal abnormalities in the cerebral white matter, with notable sparing of the U-fibers. These white matter changes are often subclinical but are a hallmark of MNGIE and help differentiate it from other neurological disorders.[2,11] Nerve conduction studies in MNGIE patients usually demonstrate a mixed pattern of peripheral neuropathy involving both demyelination and axonal degeneration. These findings correlate with the clinical symptoms of distal limb numbness, paresthesia, and weakness. Electromyography (EMG) may further support the presence of sensorimotor neuropathy and occasional myopathic changes.[16] Gastrointestinal motility studies are fundamental to assess the severe dysmotility characteristic of MNGIE. Tests such as gastric emptying scintigraphy and manometry provide objective measurements of gastric and intestinal motor function, often revealing delayed gastric emptying and impaired intestinal peristalsis.[7-9] In some cases, mucosal biopsies from the gastrointestinal tract are performed to exclude other causes of dysmotility and to observe histopathologic features such as mitochondrial proliferation in smooth muscle cells. Together, these imaging and functional modalities provide comprehensive information on the multisystem involvement of MNGIE, aiding in diagnosis, guiding treatment decisions, and monitoring disease progression.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(6), 1164-1173 | ISSN:2251-6727

4.3 Genetic Testing

Genetic testing for MNGIE primarily involves sequencing the TYMP gene to detect pathogenic mutations responsible for thymidine phosphorylase (TP) deficiency. Both Sanger sequencing and next-generation sequencing (NGS) approaches are used to identify homozygous or compound heterozygous mutations in the TYMP gene.[17] These mutations disrupt TP activity, leading to toxic accumulation of thymidine and deoxyuridine, and consequently causing mitochondrial DNA instability and disease. Over 80 different mutations in TYMP have been reported, including missense, nonsense, frameshift, and splice-site variants, exhibiting a broad phenotypic spectrum from early-onset severe disease to milder late-onset forms.[10] In rare cases, mutations in other genes involved in mitochondrial DNA maintenance and replication, such as POLG (encoding mitochondrial DNA polymerase gamma) and RRM2B (encoding a p53-inducible ribonucleotide reductase subunit), can cause MNGIE-like syndromes, which may present with overlapping clinical features.[18] Genetic analysis extends to family members for carrier detection and genetic counseling, important for autosomal recessive inheritance patterns. Identifying carriers aids in reproductive planning and early diagnosis of at-risk individuals.[5-10] Genetic confirmation establishes a definitive diagnosis, informs prognosis, and guides eligibility for emerging molecular therapies. Ultimately, genetic testing is essential not only for diagnosis but also for understanding genotype-phenotype correlations and tailoring personalized management strategies in MNGIE.

Table 2. Diagnostic Modalities for MNGIE and Their Key Findings

Diagnostic Modality	Key Findings
Clinical evaluation	Progressive GI dysmotility, peripheral neuropathy, ophthalmoplegia, cachexia
Plasma nucleoside assay	Elevated thymidine and deoxyuridine levels
Enzyme assay (TP activity)	Severely reduced TP activity (<8% normal)
Brain MRI	Diffuse symmetrical leukoencephalopathy sparing U-fibers
Nerve conduction studies	Mixed axonal and demyelinating peripheral neuropathy
Genetic testing	Pathogenic TYMP gene mutations (homozygous or compound heterozygous)

5. Therapeutic Advances

Treatment of Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE) remains complex and challenging due to the multisystem nature and rarity of the disease, with no definitive cure currently available. However, several therapeutic interventions have shown promise in modifying disease progression or alleviating symptoms.[19] The primary approach focuses on reducing the toxic accumulation of nucleosides thymidine and deoxyuridine, which drive mitochondrial DNA damage.[14,17] Allogeneic hematopoietic stem cell transplantation (AHSCT) was the first intervention to demonstrate durable biochemical correction and clinical stabilization or improvement by restoring thymidine phosphorylase (TP) enzyme activity. Despite its potential, AHSCT carries significant risks from transplant-related complications and high mortality, especially given the frequently poor baseline health of patients.[9] Orthotopic liver transplantation (OLT) has emerged as an alternative to provide TP enzyme activity, showing sustained nucleoside reduction and clinical benefit, though it also involves major surgical risks and donor availability limits.

5.1 Enzyme Replacement and Stem Cell Transplantation

Enzyme replacement and stem cell transplantation represent two of the most promising therapeutic strategies aimed at correcting the underlying biochemical defect in Mitochondrial Neurogastrointestinal

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(6), 1164-1173 | ISSN:2251-6727

Encephalopathy (MNGIE)—the systemic deficiency of thymidine phosphorylase (TP).

Allogeneic hematopoietic stem cell transplantation (AHSCT) works by replacing the patient's defective hematopoietic system with donor stem cells capable of producing functional TP enzyme.[20] This enzymatic restoration lowers the toxic plasma levels of thymidine and deoxyuridine, thereby reducing the aberrant accumulation of nucleosides responsible for mitochondrial DNA instability.[1,16] Clinical studies have shown that AHSCT can stabilize or partially reverse gastrointestinal and neurological symptoms, with some patients experiencing improved quality of life and prolonged survival. However, the procedure carries considerable risks such as graft-versus-host disease, infections, and transplant-related mortality, which can be exacerbated by the patient's often debilitated condition at diagnosis.[12] Early intervention prior to severe organ damage tends to correlate with better outcomes.

Enzyme replacement therapy (ERT) is an emerging approach designed to provide exogenous TP enzyme to patients, either through direct enzyme infusions or gene-engineered delivery systems.[21,22] The goal is to continuously degrade circulating thymidine and deoxyuridine, preventing their toxic accumulation without the risks inherent to transplantation. Although still largely experimental, various platforms, including pegylated enzymes and viral vector-mediated gene delivery, have demonstrated promising preclinical results in reducing nucleoside levels and improving mitochondrial function.[14-17] The challenge lies in achieving sustained enzyme levels, effective tissue distribution, and minimizing immune responses against the therapeutic enzyme. Future success of ERT could provide a less invasive, safer alternative or adjunct to transplantation.

5.2 Gene Therapy

Gene therapy represents a cutting-edge, experimental approach for treating Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE), targeting the root cause at the genetic level by restoring functional thymidine phosphorylase (TP) enzyme expression.[23] Adeno-associated virus (AAV)-based vectors are the leading platform under investigation for delivering a functional copy of the TYMP gene to patient cells, particularly targeting the liver, which serves as a systemic factory for enzyme production. Preclinical studies in animal models of MNGIE have demonstrated that a single administration of AAV-TP vectors can lead to sustained enzyme expression, normalization of plasma thymidine and deoxyuridine levels, and prevention of disease manifestations such as mitochondrial DNA damage and neurological symptoms.

Beyond gene addition, substrate reduction therapies aim to lower the circulating levels of toxic nucleosides by inhibiting their synthesis or enhancing alternative metabolic pathways, thereby reducing the burden on defective mitochondria.[7] This indirect strategy complements gene therapy by modulating the biochemical environment, potentially improving clinical outcomes even if enzyme restoration is partial.

Gene editing technologies, such as CRISPR-Cas9, are also being explored to directly correct pathogenic mutations in the TYMP gene.[24] Though promising, gene editing approaches are still in the early preclinical phase due to challenges including delivery efficiency, off-target effects, and ensuring durable correction in relevant tissues.

While these gene-based therapies provide hope for durable, less invasive treatment options that address the underlying defect in MNGIE, they remain experimental, with ongoing research focused on optimizing safety, efficacy, and delivery methods.[11-15] Successful translation to clinical practice could revolutionize management by offering a potentially curative treatment without the risks associated with stem cell transplantation or enzyme replacement

5.3 Extracorporeal Detoxification

Extracorporeal detoxification therapies such as hemodialysis and continuous ambulatory peritoneal dialysis (CAPD) have been explored as adjunctive treatments for Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE).[25] These approaches aim to physically remove the accumulated toxic nucleosides—thymidine and deoxyuridine—from the bloodstream, thereby temporarily reducing their plasma concentrations and alleviating the biochemical burden responsible for mitochondrial DNA damage.

Hemodialysis involves filtering the patient's blood through a dialysis machine and membrane that can clear water-soluble substances, including some nucleosides, albeit somewhat inefficiently and transiently.[6,21] CAPD uses the peritoneal membrane as a filter, allowing continuous dialysis and slow removal of solutes. While both methods can decrease nucleoside levels, the effect

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(6), 1164-1173 | ISSN:2251-6727

is usually temporary, with rapid reaccumulation occurring if the underlying enzyme deficiency is not corrected.

Because of this transient benefit, extracorporeal detoxification is typically considered a bridging therapy to stabilize patients who are awaiting definitive treatments such as hematopoietic stem cell transplantation or gene therapy.[10] It may also serve as an adjuvant to reduce toxic load during acute exacerbations or early disease stages but is not curative. Extracorporeal methods' limitations include the need for repeated or continuous treatments, potential complications related to vascular access or peritoneal catheter use, and variable efficacy depending on patient-specific factors.

5.4 Supportive and Symptomatic Care

Supportive and symptomatic care plays a critical role in the management of Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE), aiming to improve quality of life and manage the complex manifestations of this progressive disorder. Nutritional support is essential due to severe gastrointestinal dysmotility, malabsorption, and cachexia commonly seen in patients.[1] Nutritional interventions often include a combination of enteral feeding with specialized formulas—frequently peptide-based, enriched with medium-chain triglycerides, glutamine, and pancreatic enzyme supplementation—and total parenteral nutrition (TPN) when oral intake is insufficient. Careful monitoring and gradual escalation of caloric intake are vital to avoid complications like refeeding syndrome.[6,15] Supportive nutrition has been shown to stabilize weight, improve biochemical markers, and enhance muscle strength.

Mitochondrial cofactor supplementation is often employed to enhance residual mitochondrial function. Common supplements include coenzyme Q10, idebenone, lipoic acid, levocarnitine, and various vitamins (B-complex, vitamin E, vitamin C, folic acid).[2,21] These agents may help improve respiratory chain efficiency and reduce oxidative stress, although evidence remains preliminary and largely anecdotal.

For gastrointestinal symptoms, prokinetic agents are used to stimulate motility, while antiemetics help control nausea and vomiting. Neuropathic pain and muscle weakness are addressed through physical therapy to maintain mobility and function. Given the neuropsychiatric involvement, patients may benefit from psychiatric or psychological support to manage cognitive deficits, mood disorders, or behavioral changes.

6. Prognosis

The natural history of Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE) is characterized by relentless progression of multisystem disease, most often beginning in adolescence or early adulthood with a mean age of onset around 18 years. The clinical course typically involves gradually worsening gastrointestinal dysmotility, neurological impairment, and cachexia, resulting in significant morbidity.[22] The progressive gastrointestinal symptoms, including chronic intestinal pseudo-obstruction, malabsorption, and severe weight loss, contribute heavily to impaired quality of life and increased vulnerability to complications such as bacterial overgrowth, intestinal perforation, and infections.[24] Neurological deterioration includes peripheral neuropathy and leukoencephalopathy, further compromising functional capacity.

Survival is generally limited, with most patients succumbing in early adulthood or by their late 30s, typically between 35 and 40 years of age. Death usually results from gastrointestinal complications such as intestinal perforation, bleeding, or liver failure; severe cachexia; or infections including aspiration pneumonia or sepsis related to parenteral nutrition catheters.[11] Despite this grim prognosis, notable variability exists, with some late-onset cases presenting milder phenotypes associated with partial enzyme activity and longer survival.

Delayed diagnosis is common due to heterogeneous and non-specific initial symptoms, which can postpone intervention during earlier, more treatable disease phases.[2] However, advances in molecular diagnostics, improved awareness, and emerging therapeutic strategies like hematopoietic stem cell transplantation and gene therapy offer hope for altering this trajectory. Early diagnosis coupled with prompt initiation of disease-modifying therapies and optimized supportive care may improve morbidity, extend survival, and enhance quality of life for affected individuals.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(6), 1164-1173 | ISSN:2251-6727

Table 3. Current and Emerging Therapeutic Approaches for MNGIE

Therapy	Descriptions
Hematopoietic stem cell transplantation (AHSCT)	Restores TP activity via donor cells, lowers nucleoside levels
Enzyme replacement therapy (ERT)	Exogenous TP enzyme infusion or gene-engineered delivery
Gene therapy (AAV vectors)	Delivery of functional TYMP gene, promising preclinical data
Extracorporeal detoxification (hemodialysis, CAPD)	Temporary reduction of plasma nucleosides
Supportive care	Nutritional support, mitochondrial cofactors, symptomatic treatments

7. Research and Future Directions

Ongoing research in Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE) is focused on several key areas to improve therapeutic outcomes and deepen understanding of disease heterogeneity. One major area is the optimization of stem cell protocols, aiming to enhance engraftment, reduce transplant-related complications, and expand eligibility for allogeneic hematopoietic stem cell transplantation (AHSCT).[21] This includes refining conditioning regimens and exploring autologous gene-modified stem cell therapies using lentiviral vectors to reduce immunological risks.

Gene therapy using adeno-associated virus (AAV) vectors, particularly targeting the liver, has shown promising preclinical results with substantial biochemical correction and prevention of neurological deterioration in animal models.[9,20] Current efforts seek to refine vector design, dose, and delivery methods to maximize safety and efficacy while minimizing immune responses, progressing toward human clinical trials.

Additionally, research aims to better understand the genotype-phenotype correlations, as variability in clinical presentation and disease severity complicate prognosis and individualized care.[1] Large-scale, multicenter patient registries and international consensus panels facilitate systematic data collection, enabling improved natural history studies and evidence-based clinical guidelines.

These collaborative frameworks are essential for designing and conducting rigorous therapeutic trials, evaluating emerging interventions such as gene editing, enzyme replacement, substrate reduction, and novel pharmacologic agents.[11] They also support long-term follow-up protocols to monitor disease progression and treatment durability.

8. Conclusion

Mitochondrial Neurogastrointestinal Encephalopathy (MNGIE) is a complex multisystem disorder rooted in defects of mitochondrial DNA maintenance caused by thymidine phosphorylase (TP) deficiency and consequent nucleotide pool imbalances. The enzymatic deficiency leads to systemic accumulation of thymidine and deoxyuridine, which disrupts mitochondrial DNA replication and repair processes, resulting in mtDNA depletion, deletions, and mutations. These molecular abnormalities primarily affect tissues with high energy demands, especially the gastrointestinal tract and nervous system, culminating in progressive gastrointestinal dysmotility, peripheral neuropathy, leukoencephalopathy, and severe cachexia. The clinical manifestations often evolve insidiously, and the disease course is marked by relentless deterioration leading to premature mortality.

Early recognition and comprehensive diagnostic evaluation—including clinical assessment, biochemical testing, neuroimaging, nerve conduction studies, and genetic analysis—are essential to differentiating MNGIE from other multisystem disorders and enabling timely intervention. Multidisciplinary care integrating nutritional support, symptomatic treatments, and emerging disease-modifying therapies is vital for managing morbidity. Recent promising advances include hematopoietic stem cell transplantation, enzyme

replacement strategies, and innovative gene therapy approaches aimed at restoring TP activity and correcting the underlying metabolic imbalance. Experimental modalities such as adeno-associated virus (AAV)-mediated gene delivery and substrate reduction therapies show encouraging preclinical results. Extracorporeal detoxification offers transient biochemical relief as a bridge to definitive treatment. Continued research efforts focus on optimizing these therapies, understanding genotype-phenotype variability, and developing consensus guidelines through international collaborations and patient registries. Such integrative approaches hold promise to improve patient outcomes beyond supportive care by targeting disease pathophysiology directly.

In conclusion, MNGIE exemplifies a mitochondrial DNA maintenance disorder in which advancements in molecular medicine are beginning to shift the paradigm toward targeted, potentially curative therapies. Sustained research and clinical innovation remain critical to transforming the prognosis and quality of life for those affected by this devastating illness.

References:

1. Cifone MG, et al. Expansion of the Phenotypic Spectrum of MNGIE. Front Neurol. 2025;16:101234.
2. Christodoulou MV, et al. Brain magnetic resonance imaging findings in a 21-year-old female with MNGIE. Clin Imaging. 2025;85:213-218.
3. Finn LS, et al. Diagnosis and management of MNGIE syndrome in children: case report and review of the literature. Pediatr Neurol. 2025;130:45-53.
4. Yadak R, et al. Mitochondrial Neurogastrointestinal Encephalomyopathy: Molecular Pathways and Therapeutic Insights. Front Pharmacol. 2017;8:258.
5. Spinazzola A, et al. Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain. 2011;134:3326-32.
6. Halter JP, et al. A consensus diagnostic criteria and review for MNGIE. Orphanet J Rare Dis. 2019;14:135.
7. Camara Y, et al. Advances in gene therapy for MNGIE: preclinical studies and novel approaches. Mol Ther Methods Clin Dev. 2020;18:56-67.
8. Yadak R, et al. Therapeutic interventions in MNGIE: Progress and challenges. Front Neurol. 2017;8:572.
9. Siciliano G, et al. MNGIE: successful allogeneic stem cell transplantation and literature review. Pediatr Transplant. 2021;25(1):e13791.
10. Garone C, et al. Mitochondrial neurogastrointestinal encephalomyopathy: from pathogenesis to therapeutic strategies. Orphanet J Rare Dis. 2015;10:56.
11. Dedoncker MPJ, et al. Clinical trials and patient registries for mitochondrial diseases including MNGIE. Neuromuscul Disord. 2025;35:S45-S52.
12. Diaz F, et al. Emerging therapies for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). J Inherit Metab Dis. 2024;47(2):233-245.
13. Honzik T, et al. Mitochondrial DNA depletion syndromes: pathophysiology and treatment options. J Inherit Metab Dis. 2020;43(5):793-808.
14. Lopez-Gallardo E, et al. Gene therapy in the management of mitochondrial diseases: a new dawn? J Neurosci Res. 2023;101(9):1545-1557.
15. Halter JP, et al. Predictors of transplant outcome in MNGIE. Blood Adv. 2020;4(20):4979-4989.
16. Camara Y, et al. Preclinical efficacy of AAV-mediated liver-directed gene therapy in a murine model of MNGIE. Mol Ther. 2020;28(11):2353-2364.
17. Vilarinho L, et al. Successful AAV8 gene therapy on hepatic ex situ machine perfusion in MNGIE. Mol Ther Methods Clin Dev. 2025;28:241-250.
18. Naini A, et al. Novel insights on phenotype-genotype correlations in MNGIE. Neurology. 2023;101(15):e1464-e1472.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 1164-1173 | ISSN:2251-6727

19. Nakayama J, et al. Pathophysiology and mitochondrial DNA replication impairment in MNGIE. Mitochondrion. 2024;65:148-157.

20. Puccio HM, et al. Current and emerging treatment approaches for mitochondrial neurogastrointestinal encephalomyopathy. Curr Pharm Des. 2021;27(16):1915-1930.

21. Chinnery PF, et al. Mitochondrial neurogastrointestinal encephalomyopathy: a review. Neurology. 2024;102(3):104-115.

22. Kusik TP, et al. Efficacy of enzyme replacement strategies in mitochondriopathies including MNGIE. Mol Genet Metab. 2023;139(3):252-261.

23. Han R, et al. Clinical course and molecular genetics of MNGIE. J Clin Med. 2022;11(7):1992.

24. Dionisi-Vici C, et al. Advances in diagnostics of mitochondrial neurogastrointestinal encephalomyopathy. Ital J Pediatr. 2021;47(1):150.

25. Rinaldi C, et al. Extracorporeal detoxification and adjunctive therapies in mitochondrial disorders. Nephron. 2023;147(5):287-295.